
Tony Pourmohamad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7834029/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bayesian Optimization Via Barrier Functions. Journal of Computational and Graphical Statistics, 2022, 31, 74-83.	1.7	11
2	Gaussian Process Modeling for Dissolution Curve Comparisons. Journal of the Royal Statistical Society Series C: Applied Statistics, 2022, 71, 331-351.	1.0	1
3	The Utility of Novel Urinary Biomarkers in Mice for Drug Development Studies. International Journal of Toxicology, 2021, 40, 15-25.	1.2	3
4	A <scp>Phase I</scp> doseâ€escalation study of <scp>DCLL9718S</scp> , an antibodyâ€drug conjugate targeting <scp>C</scp> â€type lectinâ€like moleculeâ€1 (<scp>CLL</scp> â€1) in patients with acute myeloid leukemia. American Journal of Hematology, 2021, 96, E175-E179.	4.1	3
5	Validating Container Closure Integrity with Statistically Based Tests. PDA Journal of Pharmaceutical Science and Technology, 2021, 75, pdajpst.2020.012622.	0.5	0
6	Bimodal expression of potential drug target CLLâ€1 (CLEC12A) on CD34+ blasts of AML patients. European Journal of Haematology, 2021, 107, 343-353.	2.2	5
7	Constrained Optimization. SpringerBriefs in Statistics, 2021, , 69-94.	0.4	0
8	The Statistical Filter Approach to Constrained Optimization. Technometrics, 2020, 62, 303-312.	1.9	10
9	Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies. International Journal of Toxicology, 2019, 38, 12-22.	1.2	19
10	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 3220-3228.	7.0	179
11	Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 339-351.	2.3	14
12	Multivariate Stochastic Process Models for Correlated Responses of Mixed Type. Bayesian Analysis, 2016, 11, .	3.0	14
13	Silent Intralesional Microhemorrhage as a Risk Factor for Brain Arteriovenous Malformation Rupture. Stroke, 2012, 43, 1240-1246.	2.0	78
14	Brain Arteriovenous Malformation Multiplicity Predicts the Diagnosis of Hereditary Hemorrhagic Telangiectasia. Stroke, 2012, 43, 72-78.	2.0	75
15	Evaluating Performance of the Spetzler-Martin Supplemented Model in Selecting Patients With Brain Arteriovenous Malformation for Surgery. Stroke, 2012, 43, 2497-2499.	2.0	22
16	Cerebellar Arteriovenous Malformations. Neurosurgery, 2012, 71, 1111-1124.	1.1	87
17	An Admission Bioclinical Score to Predict 1-Year Outcomes in Patients Undergoing Aneurysm Coiling. Stroke, 2012, 43, 1253-1259.	2.0	28
18	Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. NeuroReport, 2012, 23, 627-630.	1.2	10